Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
Novartis pays $678 million to settle US kickback allegationsAnother nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other Share XNovartis pays $678 million to settle US kickback allegationshttps://pharmaphorum.com/news/novartis-pays-678-million-to-settle-us-kickback-allegations/
Indivior ex-CEO could face jail time after opioid convictionThe resignation of Indivior chief executive Shaun Thaxter this week was swiftly followed by a guilty plea – Share XIndivior ex-CEO could face jail time after opioid convictionhttps://pharmaphorum.com/news/indivior-ex-ceo-could-face-jail-time-after-opioid-conviction/
Bayer agrees $10 billion-plus deal to settle Roundup cancer claimsGerman pharma and chemicals group Bayer may finally have put long-running litigation over its weedkiller Roundup in its Share XBayer agrees $10 billion-plus deal to settle Roundup cancer claimshttps://pharmaphorum.com/news/bayer-agrees-10-billion-plus-deal-to-settle-roundup-cancer-claims/
Litigation-weary J&J pulls Baby Powder talc in North AmericaJohnson and Johnson has opted to withdraw one its iconic products – talc-based Baby Powder – from sale Share XLitigation-weary J&J pulls Baby Powder talc in North Americahttps://pharmaphorum.com/news/litigation-weary-jj-pulls-baby-powder-talc-in-north-america/
‘Delusional’ Shkreli refused prison release to fight coronavirusMartin Shkreli, the pharma CEO once branded as America’s most hated man has been denied release from prison after a Share X‘Delusional’ Shkreli refused prison release to fight coronavirushttps://pharmaphorum.com/news/delusional-shkreli-refused-prison-release-to-fight-coronavirus/
Amarin hit hard as generics loom for fish oil drug VascepaGeneric drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share XAmarin hit hard as generics loom for fish oil drug Vascepahttps://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
UK court imposes safety rules on off-label use of Avastin in wet-AMDBayer has said a new UK court ruling could limit off-label use of Roche’s Avastin in ophthalmology by Share XUK court imposes safety rules on off-label use of Avastin in wet-AMDhttps://pharmaphorum.com/news/uk-appeal-court-upholds-use-of-avastin/
Mallinckrodt proposes $1.6bn deal to settle opioid litigationMallinckrodt is placing a $1.6 billion settlement package on the table as it tries to bring litigation related Share XMallinckrodt proposes $1.6bn deal to settle opioid litigationhttps://pharmaphorum.com/news/mallinckrodt-proposes-1-6bn-deal-to-settle-opioid-litigation/
